Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Instylla Scores $25.4M Series B Financing

BEDFORD, MA, Instylla has announced a $25.4 million Series B financing.
Instylla, a privately held company developing minimally invasive liquid embolic products designed for use in peripheral vascular embolotherapy today announced closure of $25.4 million Series B financing. Participants in this latest round of financing included the new investors Excelestar Ventures, Catalyst Health Ventures, and Amed Ventures. Existing investors Ascension Ventures, Sparta Group and Incept also participated. As part of the financing Tasneem Dohadwala and Darshana Zaveri will join the board. These funds are anticipated to see Instylla through several prospective clinical trials, including a pivotal trial in the United States, in preparation for market entry.

Instylla is a privately held company in Bedford, MA focused on developing peripheral liquid embolic products based on its proprietary hydrogel technology to improve patient outcomes, procedure efficiency, and enable new therapies. The company was founded by Incept LLC in 2017 and is funded by several leading venture capital groups and Instylla principals.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors

Featured Reading